LT2827900T - Amorfinė kieta dispersija, skirta panaudoti smegenų vėžio gydymui - Google Patents

Amorfinė kieta dispersija, skirta panaudoti smegenų vėžio gydymui

Info

Publication number
LT2827900T
LT2827900T LTEP13714497.8T LT13714497T LT2827900T LT 2827900 T LT2827900 T LT 2827900T LT 13714497 T LT13714497 T LT 13714497T LT 2827900 T LT2827900 T LT 2827900T
Authority
LT
Lithuania
Prior art keywords
treatment
solid dispersion
amorphous solid
brain cancer
brain
Prior art date
Application number
LTEP13714497.8T
Other languages
English (en)
Lithuanian (lt)
Inventor
Patrice Lee
Shannon WINSKI
Kevin Koch
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2827900(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of LT2827900T publication Critical patent/LT2827900T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
LTEP13714497.8T 2012-03-23 2013-03-25 Amorfinė kieta dispersija, skirta panaudoti smegenų vėžio gydymui LT2827900T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23
PCT/US2013/033751 WO2013142875A1 (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Publications (1)

Publication Number Publication Date
LT2827900T true LT2827900T (lt) 2018-05-10

Family

ID=48048296

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13714497.8T LT2827900T (lt) 2012-03-23 2013-03-25 Amorfinė kieta dispersija, skirta panaudoti smegenų vėžio gydymui

Country Status (30)

Country Link
US (3) US20150110780A1 (OSRAM)
EP (4) EP4252855A3 (OSRAM)
JP (6) JP2015514075A (OSRAM)
KR (3) KR102160462B1 (OSRAM)
CN (2) CN109223791A (OSRAM)
AU (4) AU2013234921A1 (OSRAM)
CA (1) CA2867723C (OSRAM)
CL (1) CL2014002497A1 (OSRAM)
CO (1) CO7071139A2 (OSRAM)
CY (2) CY1120204T1 (OSRAM)
DK (2) DK2827900T3 (OSRAM)
ES (2) ES2673165T3 (OSRAM)
HR (1) HRP20180659T1 (OSRAM)
HU (2) HUE053156T2 (OSRAM)
IL (3) IL234627B (OSRAM)
LT (1) LT2827900T (OSRAM)
MX (1) MX354024B (OSRAM)
MY (2) MY202114A (OSRAM)
NZ (4) NZ756264A (OSRAM)
PH (2) PH12021550360A1 (OSRAM)
PL (2) PL2827900T3 (OSRAM)
PT (2) PT2827900T (OSRAM)
RS (1) RS57140B1 (OSRAM)
RU (2) RU2018138976A (OSRAM)
SG (1) SG11201405954YA (OSRAM)
SI (2) SI3400943T1 (OSRAM)
SM (1) SMT201800251T1 (OSRAM)
TR (1) TR201808450T4 (OSRAM)
UA (1) UA122044C2 (OSRAM)
WO (1) WO2013142875A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852058C (en) 2011-10-14 2021-06-01 Array Biopharma Inc. A solid dispersion of n4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine
CA2852060A1 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
LT2827900T (lt) 2012-03-23 2018-05-10 Array Biopharma, Inc. Amorfinė kieta dispersija, skirta panaudoti smegenų vėžio gydymui
WO2018165015A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
EA201992573A1 (ru) 2017-04-28 2020-04-06 Сиэтл Дженетикс, Инк. Лечение her2-положительных злокачественных новообразований
MX2020008015A (es) 2018-01-31 2020-10-16 Deciphera Pharmaceuticals Llc Terapia de combinación para el tratamiento de la mastocitosis.
EP3746059A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
CN112566665A (zh) * 2018-04-09 2021-03-26 莫舍·吉拉迪 用TTFields和Aurora激酶抑制剂治疗肿瘤
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
KR20250057151A (ko) 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
US20020137731A1 (en) 2000-05-30 2002-09-26 Gewirtz David A. Combination of radiation and vitamin D3 analogs for the treatment of cancer
RU2350605C2 (ru) 2003-08-14 2009-03-27 Эррей Байофарма Инк. Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆（科克）有限公司 癌症治疗方法
RU2006142420A (ru) 2004-06-03 2008-07-20 Смитклайн Бичам (Корк) Лимитед (Ie) Способ лечения рака
WO2007059257A2 (en) 2005-11-15 2007-05-24 Array Biopharma Inc. N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
CN101374864A (zh) 2006-01-31 2009-02-25 诺瓦提斯公司 用于靶向癌症的il-17拮抗性抗体
WO2009042618A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
KR20160125535A (ko) 2008-03-18 2016-10-31 제넨테크, 인크. 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
CA2852058C (en) 2011-10-14 2021-06-01 Array Biopharma Inc. A solid dispersion of n4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine
CA2852060A1 (en) * 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
LT2827900T (lt) 2012-03-23 2018-05-10 Array Biopharma, Inc. Amorfinė kieta dispersija, skirta panaudoti smegenų vėžio gydymui

Also Published As

Publication number Publication date
CA2867723A1 (en) 2013-09-26
KR102160462B1 (ko) 2020-09-28
JP6898960B2 (ja) 2021-07-07
IL234627B (en) 2018-10-31
CN104203279A (zh) 2014-12-10
PL3400943T3 (pl) 2021-06-14
AU2017272232C1 (en) 2019-08-15
DK2827900T3 (en) 2018-05-07
UA122044C2 (uk) 2020-09-10
US20190255051A1 (en) 2019-08-22
MY202114A (en) 2024-04-04
EP3400943A1 (en) 2018-11-14
KR102490961B1 (ko) 2023-01-19
RU2018138976A3 (OSRAM) 2022-04-08
RU2018138976A (ru) 2018-12-06
KR102317166B1 (ko) 2021-10-26
SI2827900T1 (en) 2018-06-29
AU2019203618A1 (en) 2019-06-13
PT2827900T (pt) 2018-06-14
JP2021178820A (ja) 2021-11-18
NZ630843A (en) 2017-01-27
NZ756264A (en) 2022-09-30
NZ741615A (en) 2019-10-25
CO7071139A2 (es) 2014-09-30
PH12021550360A1 (en) 2023-04-03
EP3842044A1 (en) 2021-06-30
JP2015514075A (ja) 2015-05-18
JP2022190126A (ja) 2022-12-22
JP2017141302A (ja) 2017-08-17
KR20140139009A (ko) 2014-12-04
MX2014011437A (es) 2014-11-10
KR20210131426A (ko) 2021-11-02
PH12014502032A1 (en) 2014-11-24
ES2855142T3 (es) 2021-09-23
WO2013142875A1 (en) 2013-09-26
PL2827900T3 (pl) 2018-08-31
AU2017272232B2 (en) 2019-02-28
IL269205B (en) 2020-06-30
CL2014002497A1 (es) 2014-11-14
MX354024B (es) 2018-02-08
US20150110780A1 (en) 2015-04-23
RS57140B1 (sr) 2018-07-31
US11504370B2 (en) 2022-11-22
EP2827900B1 (en) 2018-03-21
PT3400943T (pt) 2021-02-02
SG11201405954YA (en) 2014-10-30
JP2019081792A (ja) 2019-05-30
AU2021261849A1 (en) 2021-12-02
EP4252855A2 (en) 2023-10-04
NZ724544A (en) 2018-05-25
EP4252855A3 (en) 2023-11-15
HK1206276A1 (en) 2016-01-08
MY174883A (en) 2020-05-20
AU2019203618B2 (en) 2021-08-05
EP2827900A1 (en) 2015-01-28
HUE053156T2 (hu) 2021-06-28
CN109223791A (zh) 2019-01-18
SMT201800251T1 (it) 2018-07-17
RU2014142700A (ru) 2016-05-20
RU2672575C2 (ru) 2018-11-16
IL269205A (en) 2019-11-28
DK3400943T3 (da) 2021-02-08
EP3400943B1 (en) 2020-12-02
AU2013234921A1 (en) 2014-10-02
CN104203279B (zh) 2018-10-30
IL261659A (en) 2018-10-31
CY1123837T1 (el) 2022-05-27
JP7404485B2 (ja) 2023-12-25
CY1120204T1 (el) 2018-12-12
JP2024019526A (ja) 2024-02-09
SI3400943T1 (sl) 2021-03-31
AU2017272232A1 (en) 2018-01-04
TR201808450T4 (tr) 2018-07-23
ES2673165T3 (es) 2018-06-20
KR20200115656A (ko) 2020-10-07
HRP20180659T1 (hr) 2018-06-01
CA2867723C (en) 2022-11-08
US20230190749A1 (en) 2023-06-22
HUE037966T2 (hu) 2018-09-28

Similar Documents

Publication Publication Date Title
LT2827900T (lt) Amorfinė kieta dispersija, skirta panaudoti smegenų vėžio gydymui
IL235062A0 (en) Compounds and methods for antiviral therapy
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL238400A0 (en) Triazolopyrazines as brd4 inhibitors for use in cancer therapy
SG11201500685PA (en) Warm-cool beauty treatment device
IL238249A0 (en) Cancer treatment
EP2922511A4 (en) TREATMENT DEVICE FOR EYELID
IL238116B (en) A process for preparing compounds for use in the treatment of cancer
ZA201408855B (en) Flocculation treatment agent
IL239374B (en) Preparations and methods for treating brain tumors
GB201221123D0 (en) Device for photodynamic treatment
IL235127A (en) Hpn-100 for use in the treatment of nitrogen-related diseases
PL2872176T3 (pl) Karboranyloporfiryny do stosowania w leczeniu raka
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
ZA201407164B (en) Device for use in the treatment hyperbilirubinemia
GB201222563D0 (en) Cancer treatment
AU2012900796A0 (en) Pain treatment